The influence of SnoN gene silencing by siRNA on the cell proliferation and apoptosis of human pancreatic cancer cells
© Liu et al.; licensee BioMed Central. 2015
Received: 23 November 2014
Accepted: 7 April 2015
Published: 18 April 2015
The prognosis for pancreatic cancer (PC) is very poor. The SnoN gene may have a role in cell proliferation and apoptosis in human cancer. However, the influence of SnoN on cell proliferation and apoptosis in human PC cells remains unknown.
SnoN expression was assessed in SW1990 PC cell lines using real-time polymerase chain reaction (PCR). A luciferase reporter assay was used to confirm the target associations. The effect of SnoN on cell proliferation in vitro was confirmed using Cell Counting Kit-8. Apoptosis was confirmed using flow cytometry. Gene and protein expression were examined using real time PCR and Western blotting, respectively.
SnoN siRNA significantly inhibited the growth of SW1990 cells by decreasing cell proliferation (P < 0.05) and increasing cell apoptosis (P < 0.05), compared with the blank group and the negative control group. The highest inhibition of cell proliferation appeared at 3 days post-transfection. Cell apoptosis more obvious at 48 h after transfection.
In summary, our results reveal that the RNAi-mediated downregulation of SnoN effectively inhibited the proliferation of PC cells. SnoN-siRNA also enhanced SW1990 PC cell apoptosis. These findings indicate that SnoN gene plays an important role in pancreatic cancer development, and might serve as a potential therapeutic target for pancreatic cancer. However, further in vivo studies are needed to clarify the influence of SnoN gene silencing by siRNA on pancreatic cancer therapy.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/7609324661510147
Pancreatic cancer (PC) is one of the most fatal malignant diseases worldwide. The incidence of PC is lower than that of many other types of cancer. However, it is the fourth most common cause of death from cancer . Because of nonspecific incipient symptoms and early metastasis, PC is highly malignant and invasive, resulting in poor prognosis . Previous statistics for 2002–2008 from the US National Cancer Institute showed an overall 5-year relative survival rate of 5.8% and a one-year mortality rate of 90%, with a median survival of less than 6 months [3,4].
A number of studies [5-8] have showed that the development and progression of PC are linked with complex gene regulation, such as the inactivation of tumour suppressor genes, the activation of proto-oncogenes, abnormal regulation of cell proliferation and apoptosis adjustment disorders, and abnormal expression of growth factors and their receptors. In recent years, although targeted therapies in PC treatment have been gradually developed, the PC survival rate has not improved. Therefore, there is an urgent need for the identification of possible associated factors and novel therapeutic targets for PC.
The SnoN gene, a member of the Ski family of proto-oncogenes that was originally identified based on sequence homology with v-Ski, encodes an oncoprotein that can induce anchorage-independent growth of chicken and quail embryo fibroblasts when overexpressed [9-12]. SnoN is highly expressed in human cancer cells of the oesophagus, lung, vulva, stomach, ovary, pancreas, and breast [10,13-15]. SnoN overexpression in human cancer cells may result in gene amplification, transcriptional activation, and increased protein stability [14,16-19]. Moreover, SnoN was recently shown to silence the alpha fetoprotein gene, cooperating with p53 to negatively regulate transforming growth factor beta (TGF-β) signalling [19-21]. Although several previous studies investigated the effects of SnoN on the cell proliferation and apoptosis of ovarian, lung, breast, oesophageal, and colon cancers [22-26], the role SnoN plays in pancreatic cancer remain unknown.
In the present study, we established a pancreatic cancer cell line that stably silenced the SnoN gene by siRNA, and investigated the effects of SnoN on the proliferation and apoptosis of pancreatic cancer cells in vitro. This study may provide experimental evidence for gene therapy in PC.
This study was approved by the Ethics Committee of Air Force General Hospital of PLA.
The SW1990 human pancreatic cancer cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco’s modified Eagle’s medium (DMEM, HyClone, Logan, UT, USA) supplemented with 10% foetal bovine serum (FBS, HyClone, Logan, UT, USA), 100 U/mL penicillin and 100 μg/mL streptomycin. Cells were maintained in a 37°C humidified incubator containing 95% air and 5% CO2.
Opti-MEM medium and Lipofectamine 2000 (Lipo) were obtained from the Gibco-Invitrogen Corporation (USA). Trypsin was obtained from the HyClone Corporation (USA). The β-actin mAb was purchased from the Shanghai Kangcheng Biotechnology Corporation (Shanghai, China). The SnoN mAb was purchased from the Abcam Corporation (UK). The cDNA synthesis kit and TRIzol kit were purchased from Bao Biotechnology Corporation (Dalian, China). The RNA PCR kit was obtained from TaKaRa Corporation (Japan). The Western Blotting Detection system was obtained from Thermo Corporation (USA). The cell lysate and bicinchoninic acid (BCA) protein assay kit was purchased from Shanghai Biyuntian Biotechnology Corporation (Shanghai, China). The Cell Counting Kit-8 was obtained from Dojindo Chemical Corporation (CCK-8, Japan). The Annexin V FITC/PI assay kit was purchased from Invitrogen Corporation (USA).
SnoN siRNA sequences and PCR primers
SnoN siRNAs, labelled by florescence FAM (FAM-siRNAs), and negative control siRNAs were synthesised by Shanghai Jima Biotechnology Co., Ltd. (Shanghai, China). For the SnoN siRNA-A, the sense strand was 5’-GGGCUUUGAAUCAGCUAAATT-3’ and the antisense strand was 5’-UUUAGCUGAUUCAAAGCCCTT-3’. For the SnoN siRNA-B, the sense strand was 5’-GGCCCAGUUAAAGGAAACUTT-3’ and the antisense strand was 5’-AGUUUCCUUUAACUGGGCCTT-3’. For the SnoN siRNA-C, the sense strand was 5’-GAGGCAAGUAAGUCCAUAUTT-4’ and the antisense strand was 5’-AUAUGGACUUACUUGCCUCTT-3’. For the negative control siRNA, the sense strand was 5’-UUCUCCGAACGUGUCACGUTT-3’ and the antisense strand was 5’-ACGUGACACGUUCGGAGAATT-3’. The SnoN primers were forward, 5’-AGAGACTCTGTTTGCCCCAAGT-3’ and reverse, 5’-CATGCTAAACTTCTCCTTCATTTC-3’. The β-actin primers were forward, 5’-TTCTGTGGCATCCACGAAACT-3’ and reverse, 5’-GAAGCATTTGCGGTGGACGAT-3’.
The pancreatic cancer cells were seeded at 1×105 cells/well in 24-well plates 1 day before transfection. Medium without antibiotics was added to each well so that the cells grew to 50-70% confluence, when the transfection was conducted. The siRNA-Lipo mixture was prepared according to the manufacturer's instructions. To test the transfection efficiency of the FAM-siRNAs-Lipo mixture at different concentrations, 0, 1, 1.5 and 2 μl of Lipo were diluted with 50 μl Opti-MEM, and 0, 10, 15 and 20 μl FAM-siRNAs, respectively, were added at 50 μl/well and mixed. The 100 μl mixture was added to 300 μl of Opti-MEM including the pancreatic cancer cells. The concentrations of the four groups were 0 nmol/L, 50 nmol/L, 75 nmol/L, and 100 nmol/L, respectively. Six hours later, the medium was replaced with DMEM supplemented with 10% FBS. The expression of FAM-siRNAs was analysed with a flow cytometer.
Total RNA was extracted from cells using TRIzol reagent and reverse transcribed to cDNA using a first-strand cDNA synthesis kit according to the manufacturer’s instructions. The efficiency of the SnoN siRNAs was screened using RT-PCR and real-time PCR. Real-time PCR was conducted on the Exicycler™ 96 florescence quantitative instrument (Bioneer, Daejeon, Korea). PCR conditions and analysis were consistent with previously published methods .
SnoN protein expression was measured by Western blotting. β-actin was used as an internal control. Cells were lysed using cell lysis buffer, and the protein concentrations were quantified using the BCA assay method. Cellular proteins were dissolved in sample loading buffer and run on 7.5% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gels (100 V, constant voltage, 60 min). SnoN protein was electrotransferred onto PVDF membranes (4°C, 280 mA, 60 min). The membranes were rinsed with PBS and blocked with 10% non-fat milk in PBS for 2 h at room temperature. Primary antibody was used at the following dilutions. After primary antibody incubation, membranes were rinsed in TBS-T wash buffer 3 times for 10 min each. Then, secondary antibody (1: 2,000) was incubated for 2 h at room temperature and rinsed in TBS-T wash buffer 3 times for 10 min each. Developed films were digitised by scanning, and the optical densities were analysed with the image software.
Cell proliferation analysis
Cell viability was measured using the CCK-8 assay. Cells were seeded into 96-well plates at a density of 3 × 103 cells/well and placed in an incubator until the cells grew to confluence. Subsequently, 100 μl of CCK-8 solution was added at different time points (0, 24, 48, 72, and 96 h), and the samples were incubated at 37°C for 1.5 h. The absorbance value of each well was measured at 450 nm using a microplate reader. Non-transfected cells were set as the blank control group. Cells treated with negative siRNA transfection were set as the negative control group.
Analysis of cell apoptosis
An annexin V FITC/PI assay kit was used to detect cell apoptosis. Cells were divided into three groups (blank control group, negative control group, and transfection group). At 50% - 70% confluence, the cells were trypsinised and collected. After washing with PBS, 500 μl of annexin-binding buffer was added to resuspend the cells. After the addition of 5 μl Alexa-labelled annexin V and 1 μl PI, the cells were incubated at room temperature in the dark for 15 min and then detected by flow cytometry.
Data are presented as the mean ± standard deviation and were analysed using one-way analysis of variance (ANOVA) between groups using the SPSS 16.0 software. The differences among multiple mean values were evaluated using ANOVA. The differences between two mean values were estimated using an independent-samples t-test. The differences among the groups were analysed using the χ2 test. A P < 0.05 was considered statistically significant.
The transfection efficiency was measured by flow cytometry. When the concentrations of the FAM-siRNA mixture were 0 nmol/L, 50 nmol/L, 75 nmol/L, and 100 nmol/L, the transfection efficiencies were 9.38%, 29.9%, 57.4%, and 87.5%, respectively. We found that the optimal transfection concentration was 100 nmol/L.
Silencing efficiency of SnoN siRNAs
Screening efficiency of SnoN protein expression using Western blotting
The effect of silencing SnoN on cell proliferation
The effect of silencing SnoN on cell apoptosis
The effect of SnoN -siRNA on apoptosis of PC cells (n = 3)
0.26 ± 0.27
0.67 ± 1.38
1.77 ± 1.54
0.29 ± 0.31
0.72 ± 1.15
2.13 ± 1.97
0.56 ± 0.29*
6.94 ± 2.17*
7.45 ± 2.01*
The present work provides evidence of the importance of SnoN for cell growth in MPM. The transient SnoN-silencing caused a decrease in the proliferation rate of the pancreatic cancer cell line and an increase in the apoptosis rate.
Fewer than 5% of patients with PC achieve 5-year survival, which reveals the poor prognosis of this cancer . Therefore, to improve modern cancer therapy, numerous scholars have an ongoing interest in the identification of signalling pathways and genes that might play key roles in carcinogenesis and the development of resistance to anti-tumour drugs, with the hope of identifying putative biomarkers and/or therapeutic targets [29,30]. Applying molecular approaches, a large set of genes has been investigated for overexpression in pancreatic cancer [31-33]. However, more genes that may have an effect in the progression of PC need to be investigated.
The human SnoN gene is located at chromosome 3q26.2. SnoN is widely expressed in adult and embryonic cells. SnoN expression can be regulated at the level of gene amplification, transcriptional activation and protein stability. High expression of SnoN is found in many human cancers [22-26]. However, not all studies were consistent with upregulated SnoN expression in human cancers. While some studies reported an increase in SnoN RNA and protein in some cancer tissues and noted that this higher SnoN expression correlated with poor differentiation, deeper invasion and poor patient survival [14,15,25], others detected a decrease in SnoN expression in similar cancers, particularly in dysplastic and highly invasive cancers [34-36]. It appears that SnoN can also act as a negative regulator of tumour progression. In a recent study , SnoN was observed to cooperate with p53 in the silencing of the alpha fetoprotein gene, which is aberrantly overexpressed in liver cancer cells.
Moreover, SnoN and its structurally and functionally related protein Ski are negative regulators of TGF-β-induced transcription . The level of SnoN is directly linked to its ability to repress TGF-β signalling, but this activity may be cell-type specific . SnoN has been reported to be both a tumour promoter and a tumour suppressor . Over-expression of SnoN leads to resistance to TGF-β-induced growth arrest and formation of mammary tumours in cooperation with polyoma middle T-antigen . Furthermore, previous studies have shown that SnoN interacts directly with Smad2, Smad3, and Smad4 and represses their ability to activate expression of TGF-β target genes by disrupting the formation of an active heteromeric Smad complex, recruiting a transcriptional corepressor complex, and by blocking the interaction of transcriptional coactivators with Smad2 and Smad3 [40,41]. A number of investigations have indicated that PC is closely associated with the TGF-β/Smad pathway, and Smad4 is inactivated in nearly 60% of PC . However, the influence of SnoN gene expression on cell proliferation and apoptosis in human pancreatic cancer cells remains unclear.
Cell proliferation and apoptosis are important to the oncogenesis and chemotherapy resistance of pancreatic cancer cells . In this study, we analysed the suppressive effect of PC cell proliferation and apoptosis by siRNA silencing of SnoN expression. The results showed that the proliferation of the SnoN-siRNA-transfected cells was slower than blank and negative group, suggesting a fundamental role for SnoN in the development of PC. Therefore, through silencing SnoN gene, development of PC might be alleviated. To date, this is the first study in which RNAi-mediated SnoN expression was shown to inhibit PC cell proliferation and induce apoptosis. This finding is consistent with the previous results that SnoN promotes tumour proliferation and induces apoptosis in other cancers [14,15,25]. However, because the exact effect of SnoN expression on human cancers remains unclear, and multiple signalling pathways are thought to make important contributions to PC progression, further studies are necessary to clarify these complex mechanisms. Moreover, our study has a limitation, in that we only proved that RNAi inhibited SnoN expression in vitro. Therefore, further in vivo studies are needed to verify the effect and risk of SnoN knockdown by SnoN-siRNAs for PC therapy.
In summary, our results revealed that the RNAi-mediated downregulation of SnoN effectively inhibited the proliferation of PC cells. Meanwhile, SnoN-siRNA also enhanced PC cell apoptosis. These findings indicated that SnoN plays an important role in pancreatic cancer development, and might serve as a potential therapeutic target for pancreatic cancer. However, further in vivo studies are needed to clarify the influence of SnoN gene silencing by siRNA on pancreatic cancer therapy.
- Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144:1252–61.View ArticlePubMed CentralPubMedGoogle Scholar
- Liu SX, Xia ZS, Zhong YQ. Gene therapy in pancreatic cancer. World J Gastroenterol. 2014;20:13343–68.View ArticlePubMed CentralPubMedGoogle Scholar
- Laheru D, Biedrzycki B, Jaffee EM. Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine. Methods Mol Biol. 2013;980:175–203.View ArticlePubMedGoogle Scholar
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.View ArticlePubMedGoogle Scholar
- Kodigepalli KM, Dutta PS, Bauckman KA, Nanjundan M. SnoN/SkiL expression is modulated via arsenic trioxide-induced activation of the PI3K/AKT pathway in ovarian cancer cells. FEBS Lett. 2013;587:5–16.View ArticlePubMed CentralPubMedGoogle Scholar
- Xu K, Chen Z, Qin C, Song X. miR-7 inhibits colorectal cancer cell proliferation and induces apoptosis by targeting XRCC2. Onco Targets Ther. 2014;7:325–32.View ArticlePubMed CentralPubMedGoogle Scholar
- Song SD, Zhou J, Zhou J, Zhao H, Cen JN, Li DC. MicroRNA-375 targets the 3-phosphoinositide-dependent protein kinase-1 gene in pancreatic carcinoma. Oncol Lett. 2013;6:953–9.PubMed CentralPubMedGoogle Scholar
- Li J, Hu GH, Kong FJ, Wu KM, He B, Song K, et al. Reduced STMN1 expression induced by RNA interference inhibits the bioactivity of pancreatic cancer cell line Panc-1. Neoplasma. 2014;61:144–52.View ArticlePubMedGoogle Scholar
- Boyer PL, Colmenares C, Stavnezer E, Hughes SH. Sequence and biological activity of chicken SnoN cDNA clones. Oncogene. 1993;8:457–66.PubMedGoogle Scholar
- Nomura N, Sasamoto S, Ishii S, Date T, Matsui M, Ishizaki R. Isolation of human cDNA clones of ski and the ski-related gene, sno. Nucleic Acids Res. 1989;17:5489–500.View ArticlePubMed CentralPubMedGoogle Scholar
- Pearson-White S. SnoI, a novel alternatively spliced isoform of the ski protooncogene homolog, sno. Nucleic Acids Res. 1993;21:4632–8.View ArticlePubMed CentralPubMedGoogle Scholar
- Pearson-White S, Crittenden R. Proto-oncogene Sno expression, alternative isoforms and immediate early serum response. Nucleic Acids Res. 1997;25:2930–7.View ArticlePubMed CentralPubMedGoogle Scholar
- Jahchan NS, Ouyang G, Luo K. Expression profiles of SnoN in normal and cancerous human tissues support its tumor suppressor role in human cancer. PLoS One. 2013;8:e55794.View ArticlePubMed CentralPubMedGoogle Scholar
- Imoto I, Pimkhaokham A, Fukuda Y, Yang ZQ, Shimada Y, Nomura N, et al. SNO is a probable target for gene amplification at 3q26 in squamous-cell carcinomas of the esophagus. Biochem Biophys Res Commun. 2001;286:559–65.View ArticlePubMedGoogle Scholar
- Zhang F, Lundin M, Ristimaki A, Heikkila P, Lundin J, Isola J, et al. Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res. 2003;63:5005–10.PubMedGoogle Scholar
- Bonni S, Wang HR, Causing CG, Kavsak P, Stroschein SL, Luo K, et al. TGF-beta induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation. Nat Cell Biol. 2001;3:587–95.View ArticlePubMedGoogle Scholar
- Edmiston JS, Yeudall WA, Chung TD, Lebman DA. Inability of transforming growth factor-beta to cause SnoN degradation leads to resistance to transforming growth factor-beta-induced growth arrest in esophageal cancer cells. Cancer Res. 2005;65:4782–8.View ArticlePubMedGoogle Scholar
- Stroschein SL, Bonni S, Wrana JL, Luo K. Smad3 recruits the anaphase-promoting complex for ubiquitination and degradation of SnoN. Genes Dev. 2001;15:2822–36.PubMed CentralPubMedGoogle Scholar
- Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K. Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science. 1999;286:771–4.View ArticlePubMedGoogle Scholar
- Sun Y, Liu X, Ng-Eaton E, Lodish HF, Weinberg RA. SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor beta signaling. Proc Natl Acad Sci U S A. 1999;96:12442–7.View ArticlePubMed CentralPubMedGoogle Scholar
- Wilkinson DS, Ogden SK, Stratton SA, Piechan JL, Nguyen TT, Smulian GA, et al. A direct intersection between p53 and transforming growth factor beta pathways targets chromatin modification and transcription repression of the alpha-fetoprotein gene. Mol Cell Biol. 2005;25:1200–12.View ArticlePubMed CentralPubMedGoogle Scholar
- Deheuninck J, Luo K. Ski and SnoN, potent negative regulators of TGF-beta signaling. Cell Res. 2009;19:47–57.View ArticlePubMed CentralPubMedGoogle Scholar
- Jahchan NS, Luo K. SnoN in mammalian development, function and diseases. Curr Opin Pharmacol. 2010;10:670–5.View ArticlePubMed CentralPubMedGoogle Scholar
- Zhu Q, Krakowski AR, Dunham EE, Wang L, Bandyopadhyay A, Berdeaux R, et al. Dual role of SnoN in mammalian tumorigenesis. Mol Cell Biol. 2007;27:324–39.View ArticlePubMed CentralPubMedGoogle Scholar
- Akagi I, Miyashita M, Makino H, Nomura T, Hagiwara N, Takahashi K, et al. SnoN overexpression is predictive of poor survival in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2008;15:2965–75.View ArticlePubMedGoogle Scholar
- Nanjundan M, Cheng KW, Zhang F, Lahad J, Kuo WL, Schmandt R, et al. Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. Mol Oncol. 2008;2:164–81.View ArticlePubMed CentralPubMedGoogle Scholar
- Wang N, Wei H, Yin D, Lu Y, Zhang Y, Jiang D, et al. Cyclin D1b overexpression inhibits cell proliferation and induces cell apoptosis in cervical cancer cells in vitro and in vivo. Int J Clin Exp Pathol. 2014;7:4016–23.PubMed CentralPubMedGoogle Scholar
- Rosenberg L. Pancreatic cancer: a review of emerging therapies. Drugs. 2000;59:1071–89.View ArticlePubMedGoogle Scholar
- Ouaissi M, Silvy F, Loncle C, Ferraz Da Silva D, Martins Abreu C, Martinez E, et al. Further characterization of HDAC and SIRT gene expression patterns in pancreatic cancer and their relation to disease outcome. PLoS One. 2014;9:e108520.View ArticlePubMed CentralPubMedGoogle Scholar
- Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969–72.PubMedGoogle Scholar
- Ouaissi M, Sielezneff I, Silvestre R, Sastre B, Bernard JP, Lafontaine JS, et al. High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol. 2008;15:2318–28.View ArticlePubMedGoogle Scholar
- Gress TM, Muller-Pillasch F, Geng M, Zimmerhackl F, Zehetner G, Friess H, et al. A pancreatic cancer-specific expression profile. Oncogene. 1996;13:1819–30.PubMedGoogle Scholar
- Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, Gangeswaran R, Jones M, Terris B, et al. Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol. 2003;201:63–74.View ArticlePubMedGoogle Scholar
- Zhang X, Egawa K, Xie Y, Ihn H. The expression of SnoN in normal human skin and cutaneous keratinous neoplasms. Int J Dermatol. 2009;48:579–83.View ArticlePubMedGoogle Scholar
- Villanacci V, Bellone G, Battaglia E, Rossi E, Carbone A, Prati A, et al. Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus. Hum Pathol. 2008;39:403–9.View ArticlePubMedGoogle Scholar
- Chia JA, Simms LA, Cozzi SJ, Young J, Jass JR, Walsh MD, et al. SnoN expression is differently regulated in microsatellite unstable compared with microsatellite stable colorectal cancers. BMC Cancer. 2006;6:252.View ArticlePubMed CentralPubMedGoogle Scholar
- Band AM, Laiho M. SnoN oncoprotein enhances estrogen receptor-alpha transcriptional activity. Cell Signal. 2012;24:922–30.View ArticlePubMed CentralPubMedGoogle Scholar
- Sarker KP, Wilson SM, Bonni S. SnoN is a cell type-specific mediator of transforming growth factor-beta responses. J Biol Chem. 2005;280:13037–46.View ArticlePubMedGoogle Scholar
- Lamouille S, Derynck R. Oncogene and tumour suppressor: the two faces of SnoN. EMBO J. 2009;28:3459–60.View ArticlePubMed CentralPubMedGoogle Scholar
- Akiyoshi S, Inoue H, Hanai J, Kusanagi K, Nemoto N, Miyazono K, et al. c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads. J Biol Chem. 1999;274:35269–77.View ArticlePubMedGoogle Scholar
- Luo K, Stroschein SL, Wang W, Chen D, Martens E, Zhou S, et al. The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev. 1999;13:2196–206.View ArticlePubMed CentralPubMedGoogle Scholar
- Truty MJ, Urrutia R. Basics of TGF-beta and pancreatic cancer. Pancreatology. 2007;7:423–35.View ArticlePubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.